DevPro’s Colin Reisner Featured in ATS Philanthropy Campaign
DECEMBER 18, 2024 – DevPro Biopharma Co-Founder and CEO Colin Reisner is featured in a new video highlighting his involvement in the American Thoracic Society (ATS) Philanthropy Terrific Twenty campaign. Originally called the Terrific Ten, the circle of esteemed donors each committed to giving a minimum of $5,000 a year for five years.
Honeywell Technology to Power Devpro Biopharma’s Next-Generation Low-Emission Respiratory Inhaler
Honeywell Solstice® Air can cut metered dose inhaler greenhouse gas emissions of up to 99.9% versus current propellants
CHARLOTTE, N.C., Oct. 10, 2024 – Honeywell (NASDAQ: HON) today announced a long-term supply agreement with DevPro Biopharma to develop a respiratory inhaler that enhances the well-being of patients while reducing carbon emissions associated with the use of traditional inhalers. This new relationship with DevPro Biopharma also supports Honeywell’s alignment of its portfolio to several powerful megatrends, including the energy transition.
DevPro Biopharma Partners with Uniquity Bio to Advance Their Novel Monoclonal Antibody Targeting TSLP into Asthma and COPD Studies
Uniquity Bio Set to Start Phase 2 Clinical Trials in COPD & Asthma with Novel Anti-TSLP Monoclonal Antibody
NEW YORK — May 15, 2024 — Blackstone (NYSE:BX) today announced the launch of the Blackstone Life Sciences (“Blackstone”) portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug (IND) application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications.
DevPro Biopharma and Bespak Complete Early Feasibility Studies for New Groundbreaking Albuterol Inhaler
Ventolin-equivalent pMDI utilizes near-zero global warming potential propellant
BASKING RIDGE, NJ, & HOLMES CHAPEL, UK, May 7, 2024 – DevPro Biopharma and Bespak have announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose inhaler (pMDI) which shows comparable performance to Ventolin® HFA but with a significant reduction in greenhouse gas emissions. This breakthrough pMDI is being developed by DevPro Biopharma, a respiratory-focused clinical development accelerator, and Bespak, a leading contract development and manufacturing organization (CDMO) focused on orally inhaled and nasal drug-device combination products. Clinical studies are planned to be initiated by the end of the year to fast-track its development, as the pharmaceutical industry begins to accelerate its transition to climate-friendly respiratory care.
